Anderson, David W <br/><br/>
Neuroprotection in Parkinson models varies with toxin administration protocol.  [electronic resource] 

 -  The European journal of neuroscience  Dec 2006 
 - 3174-82 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0953-816X 
<br/><br/><label>Standard No.: </label>10.1111/j.1460-9568.2006.05192.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine--administration & dosage<br/>Animals<br/>Antigens, Nuclear--metabolism<br/>Axons--drug effects<br/>Benzothiazoles--pharmacology<br/>Biomarkers--metabolism<br/>Corpus Striatum--drug effects<br/>Disease Models, Animal<br/>Dopamine--metabolism<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Evaluation, Preclinical--methods<br/>MPTP Poisoning--physiopathology<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Nerve Degeneration--chemically induced<br/>Nerve Tissue Proteins--metabolism<br/>Neurons--drug effects<br/>Neuroprotective Agents--pharmacology<br/>Niacinamide--pharmacology<br/>Parkinsonian Disorders--chemically induced<br/>Pramipexole<br/>Substantia Nigra--drug effects<br/>Tyrosine 3-Monooxygenase--metabolism